Anzeige
Mehr »
Freitag, 10.07.2026 - Börsentäglich über 12.000 News
Paukenschlag! Diese Gratis-Aktien könnten jetzt Gold wert sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DL7T | ISIN: SE0017769995 | Ticker-Symbol: BGLA
Tradegate
08.07.26 | 14:18
10,750 Euro
-0,37 % -0,040
1-Jahres-Chart
BIOGAIA AB Chart 1 Jahr
5-Tage-Chart
BIOGAIA AB 5-Tage-Chart
RealtimeGeldBriefZeit
10,72010,88009.07.
10,74010,84009.07.
GlobeNewswire (Europe)
433 Leser
Artikel bewerten:
(2)

BioGaia AB's subsidiary introduces a complete skincare routine for babies and children

BioGaia AB's subsidiary, Biogaia New Sciences AB, is expanding its BioGaia® Skincare portfolio with two new products and an updated design across the full range. The expanded skincare line reinforces BioGaia's ambition to apply its microbiome expertise beyond gut health, oral health and immune health, supporting healthy and balanced skin from the earliest stages of life.

Building on the success of BioGaia® Probiotic Ointment, the skincare range is extended with Gentle Balm to Milk Wash and Soothing Face & Body Lotion, creating a complete skincare routine for babies and children with dry, sensitive and atopic-prone skin: body wash for cleanse, face & body lotion for hydrate, and probiotic ointment for repair. The products are developed to work in harmony with the skin microbiome and are dermatologically tested for sensitive skin.

A microbiome-first skincare routine for babies and children
BioGaia® Skincare combines probiotics, prebiotics and carefully selected plant-based ingredients. The enhanced range supports key steps in skincare:

Cleanse - Gentle Balm to Milk Wash containing prebiotics, a gentle oil-based cleanser for delicate skin which cleanses without drying and stripping the skin of its natural balance.

Hydrate and protect - Soothing Face & Body Lotion containing prebiotics, designed to balance pH, hydrate, calm and support the skin barrier for daily care.

Repair and rebalance - Probiotic Ointment, preservative- and water-free, containing only three plant-based ingredients together with a live probiotic, for dry, sensitive and atopic-prone skin. The product soothes the skin and is proven to support the skin barrier and help maintain skin microbiome balance.

All products are certified microbiome-friendly through an independent third-party certification Kind to Biome.

Babies are born with delicate, developing skin, and up to 30 percent of children experience dry, reactive or atopic-prone skin. BioGaia® Skincare is designed to support the skin microbiome, the ecosystem of beneficial microorganisms that plays a key role in maintaining skin barrier function, comfort and long-term resilience, while helping to reduce irritation and dryness.

"With decades of probiotic and microbiome research, BioGaia continues to broaden the application of its science in microbiome health. We are encouraged by the strong demand and positive consumer feedback for our probiotic ointment, Aldermis, which highlights the need for effective, microbiome-friendly skincare solutions. We are therefore excited to expand the BioGaia® Skincare portfolio with new products and an updated design across the full range, applying our expertise to skin health for babies and children with sensitive or atopic-prone skin," said Maik Lepatey, CEO of Biogaia New Sciences AB.

Availability:
BioGaia® Skincare products will be available in selected markets and have recently launched in China and the US.

References:
Gentle Balm-to-Milk Wash: Third-party clinical and instrumental evaluation including 14-day usage testing, ocular tolerability (clinical scoring + HET CAM), skin hydration (Corneometer®), transepidermal water loss (TEWL, Tewameter®); Human Repeated Insult Patch Test (HRIPT); Kind to Biome® Microbiome Friendly certification testing; and consumer perception studies. Data on file.

Soothing Face and Body Lotion: Third-party clinical and instrumental evaluation including 14-day usage testing, ocular tolerability (clinical scoring + HET CAM), skin hydration (Corneometer®), transepidermal water loss (TEWL, Tewameter®); skin pH testing, Human Repeated Insult Patch Test (HRIPT); Kind to Biome® Microbiome Friendly certification testing; and consumer perception studies. Data on file.

Probiotic Ointment: Third-party clinical and instrumental evaluation including 14-day usage testing, ocular tolerability (clinical scoring and HET-CAM), skin hydration (Corneometer®), transepidermal water loss (TEWL, Tewameter®), and skin barrier assessment; Human Repeated Insult Patch Test (HRIPT); in vitro skin and eye irritation testing (OECD 439 / OECD 492); soothing efficacy (lactic acid sting test); LongevityGuard® documentation; pilot microbiome analysis; Kind to Biome® Microbiome Friendly certification testing; and consumer perception studies. Data on file.

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Contacts:
Maik Lepatey, CEO of Biogaia New Sciences AB
Email: ml@biogaianewsciences.com
Phone: +44 7582749692

Elena Milenbakh, Head of Marketing at Biogaia New Sciences AB
Email: emi@biogaianewsciences.com
Phone: +46 769430558

About Biogaia New Sciences AB
Biogaia New Sciences AB is a wholly owned subsidiary of BioGaia AB, established in 2025 to advance microbiome research and innovation beyond BioGaia's core focus areas. The company's initial focus is skin health, developing science-based, microbiome-friendly skincare solutions for babies and children with sensitive or atopic-prone skin.

About BioGaia AB
BioGaia is a Swedish probiotics company that has been at the forefront of microbiome research for more than 35 years. BioGaia develops, manufactures, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com


© 2026 GlobeNewswire (Europe)
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.